Samik Pharm삼익제약
014950 · KOSDAQ · ₩014950 · 삼익제약
₩7,080▼ ₩640 (8.29%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | |
|---|---|---|---|---|
| Revenue | ₩16B | ₩16B | ₩15B | ₩16B |
| Cost of sales | ₩5.2B | ₩4.5B | ₩4.9B | ₩4.7B |
| Gross profit | ₩11B | ₩11B | ₩10B | ₩11B |
| Operating income | −₩228M | ₩929M | ₩49M | ₩1.1B |
| Net income | −₩1.3B | ₩1.2B | −₩1.7B | ₩221M |
| Net income to shareholders | −₩100M | ₩1.2B | −₩3.4B | ₩937M |
Balance sheet
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | |
|---|---|---|---|---|
| Total assets | ₩87B | ₩87B | ₩85B | ₩70B |
| Current assets | ₩57B | ₩58B | ₩57B | ₩45B |
| Cash and equivalents | ₩7.5B | ₩4.3B | ₩5.2B | ₩5.2B |
| Total liabilities | ₩14B | ₩17B | ₩16B | ₩16B |
| Current liabilities | ₩12B | ₩12B | ₩12B | ₩13B |
| Borrowings | ₩0 | ₩2.7B | ₩2.7B | — |
| Total equity | ₩73B | ₩70B | ₩69B | ₩54B |
| Shareholders' equity | ₩73B | ₩70B | ₩69B | ₩54B |
Cash flow
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | |
|---|---|---|---|---|
| Cash from operations | ₩662M | ₩390M | −₩1.1B | ₩1.2B |
| Capital spending | ₩277M | ₩658M | ₩2.6B | ₩28M |
| Free cash flow | ₩384M | −₩268M | −₩3.7B | ₩1.2B |
| Dividends paid | ₩368M | ₩0 | ₩36M | ₩0 |
Consolidated where available. Amounts in won.
Also known as: Samik Pharm / 삼익제약 / 014950 / KRX:014950
Source: KRX statistical information